share_log

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $20

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $20

HC Wainwright & Co.维持对Theravance Biopharma的买入,将目标股价提高至20美元
Benzinga ·  2023/05/09 06:41

HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and raises the price target from $19 to $20.

HC Wainwright & Co. 分析师道格拉斯·曹维持Theravance Biopharma(纳斯达克股票代码:TBPH)的买入并将目标股价从19美元上调至20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发